Your browser doesn't support javascript.
loading
Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes with Donor-Specific Anti-HLA Antibodies against HLA-DP.
Uchibori, Yusuke; Onodera, Koichi; Onishi, Yasushi; Komatsu, Hiroka; Takenaka, Kenta; Narumi, Yoshihiro; Watanabe, Tatsuya; Nakamura, Hiroshi; Sakurai, Kazuki; Hashimoto, Kazuki; Inokura, Kyoko; Ichikawa, Satoshi; Fukuhara, Noriko; Yokoyama, Hisayuki; Harigae, Hideo.
Afiliación
  • Uchibori Y; Department of Hematology, Tohoku University Hospital.
  • Onodera K; Department of Hematology, Tohoku University Hospital.
  • Onishi Y; Department of Hematology, Tohoku University Hospital.
  • Komatsu H; Department of Hematology, Tohoku University Hospital.
  • Takenaka K; Department of Hematology, Tohoku University Hospital.
  • Narumi Y; Department of Hematology, Tohoku University Hospital.
  • Watanabe T; Department of Hematology, Tohoku University Hospital.
  • Nakamura H; Department of Hematology, Tohoku University Hospital.
  • Sakurai K; Department of Hematology, Tohoku University Hospital.
  • Hashimoto K; Department of Hematology, Tohoku University Hospital.
  • Inokura K; Department of Hematology, Tohoku University Hospital.
  • Ichikawa S; Department of Hematology, Tohoku University Hospital.
  • Fukuhara N; Department of Hematology, Tohoku University Hospital.
  • Yokoyama H; Department of Hematology, Tohoku University Hospital.
  • Harigae H; Department of Hematology, Tohoku University Hospital.
Tohoku J Exp Med ; 261(2): 123-127, 2023 Oct 17.
Article en En | MEDLINE | ID: mdl-37558420
The presence of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) against anti-HLA-A, -B, -C, and -DRB1 in HLA-mismatched hematopoietic stem cell transplantation (HSCT) is associated with graft failure. DSAs against HLA-A, -B, -C, and -DRB1 with a mean fluorescence intensity (MFI) of greater than > 1,000 was shown to increase the risk of graft failure in single-unit umbilical cord blood transplantation (UCBT). Nevertheless, the impact of DSAs against HLA-DP or -DQ on transplantation outcomes is not fully understood. In this report, we present a case of UCBT in a patient with myelodysplastic syndrome who was positive for DSAs against HLA-DP with MFI of 1,263 before UCBT but successfully achieved neutrophil engraftment. If HLA-DP or -DQ is mismatched in UCBT, evaluating DSAs against HLA-DP or -DQ is crucial to avoid graft failure. However, the criteria for DSAs against HLA-A, -B, -C, and -DRB1 may not be directly applicable to those against HLA-DP or -DQ.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Trasplante de Células Madre Hematopoyéticas / Trasplante de Células Madre de Sangre del Cordón Umbilical Límite: Humans Idioma: En Revista: Tohoku J Exp Med Año: 2023 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Trasplante de Células Madre Hematopoyéticas / Trasplante de Células Madre de Sangre del Cordón Umbilical Límite: Humans Idioma: En Revista: Tohoku J Exp Med Año: 2023 Tipo del documento: Article